LSL Pharma Group Inc. (TSXV:LSL)

LSL Pharma Group Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.97	0.55	0.3	0.01	-	0.74
Cash & Short-Term Investments	0.97	0.55	0.3	0.01	-	0.74
Cash Growth	-80.54%	85.14%	3600.00%	-	-	-61.52%
Accounts Receivable	7.92	5.14	4.8	2.55	0.97	1.12
Other Receivables	0.01	0.37	0.15	0.13	0.07	0.22
Receivables	7.93	5.51	4.96	2.68	1.04	1.33
Inventory	17.07	12.35	9.22	4.11	2.96	4.17
Prepaid Expenses	1.45	1.19	1.01	0.41	0.21	0.13
Other Current Assets	-	4.5	-	-	0.19	0.11
Total Current Assets	27.42	24.1	15.48	7.2	4.4	6.48
Property, Plant & Equipment	37.43	32.77	22.94	14.75	13.92	12.89
Goodwill	2.52	0.16	0.16	-	-	-
Other Intangible Assets	19.36	17.47	13.27	8.93	8.98	9.39
Long-Term Deferred Tax Assets	0.22	0.22	0.22	-	-	-
Other Long-Term Assets	0.12	0.02	1.54	0.02	0.02	0.28
Total Assets	87.07	74.74	53.61	30.9	27.31	29.03

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	11.31	4.46	4.5	4.92	4.54	2.54
Accrued Expenses	-	1.77	0.79	1.06	1.58	1.17
Short-Term Debt	10.02	2.53	2.56	3.77	2.91	-
Current Portion of Long-Term Debt	1.22	0.87	1.45	5.22	1.58	1.89
Current Portion of Leases	1.18	0.69	0.45	0.12	0.14	0.19
Current Unearned Revenue	-	-	-	-	0.01	-
Other Current Liabilities	-	-	-	-	0.87	1.46
Total Current Liabilities	23.74	10.31	9.75	15.07	11.62	7.25
Long-Term Debt	25.92	26.66	12.75	4.73	7.84	7.98
Long-Term Leases	12.25	7.61	4.43	2.44	2.56	2.69
Long-Term Deferred Tax Liabilities	3.19	3.19	1.79	-	-	-
Total Liabilities	65.1	47.77	28.72	22.25	22.02	17.92

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	40.47	40.47	36.39	24.2	15.05	12.81
Additional Paid-In Capital	3.71	3.65	3.05	2.32	-	-
Retained Earnings	-22.8	-17.74	-14.92	-18.23	-9.76	-1.7
Comprehensive Income & Other	0.59	0.59	0.38	0.38	-	-
Shareholders' Equity	21.98	26.97	24.89	8.66	5.29	11.11
Total Liabilities & Equity	87.07	74.74	53.61	30.9	27.31	29.03

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	50.59	38.35	21.64	16.27	15.03	12.74
Net Cash (Debt)	-49.63	-37.8	-21.34	-16.26	-15.03	-12
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.40	-0.32	-0.20	-0.20	-0.23	-0.20
Filing Date Shares Outstanding	126.73	126.73	115.53	82.44	68.09	62.66
Total Common Shares Outstanding	126.73	126.73	115.53	82.44	68.09	62.66
Working Capital	3.68	13.79	5.72	-7.87	-7.22	-0.78
Book Value Per Share	0.17	0.21	0.22	0.10	0.08	0.18
Tangible Book Value	0.1	9.34	11.46	-0.28	-3.69	1.72
Tangible Book Value Per Share	0.00	0.07	0.10	-0.00	-0.05	0.03
Land	-	0.56	0.56	0.28	0.28	0.28
Buildings	-	5.63	5.61	3.97	3.91	3.63
Machinery	-	19.02	11.41	6.02	5.55	5.33
Construction In Progress	-	-	-	-	1.77	0.47
Leasehold Improvements	-	4.88	3.99	3.71	0.93	0.93

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error